Our Mission
We are dedicated to establishing a drug discovery and early-stage development company that is based on innovation, scientific rigor and integrity. Our goal is to create novel products to meet critical patient needs, including: Novel imaging-based diagnostic tools to improve the detection of occurrence, progression, and regression of neurological diseases; and Novel therapies to improve the treatment of human neurological conditions.
Aprinoia discovers and develops first-in-class diagnostics and therapeutics for Alzheimer’s Disease (AD) and other tau-associated neurodegenerative diseases (Tauopathies). We achieve our mission by building comprehensive internal drug discovery and development capabilities and integrative collaborations with world-class scientists, research institutions and pharmaceutical companies to bring innovative ideas and scientific discoveries to life.
Aprinoia discovers and develops first-in-class diagnostics and therapeutics for Alzheimer’s Disease (AD) and other tau-associated neurodegenerative diseases (Tauopathies). We achieve our mission by building comprehensive internal drug discovery and development capabilities and integrative collaborations with world-class scientists, research institutions and pharmaceutical companies to bring innovative ideas and scientific discoveries to life.
Tauopathies are neurodegenerative disorders caused by aggregation of Tau proteins with formations of neurofibrillary tangles.
Tau aggregates are not only found in AD, but also non-AD neurodegenerative diseases, including FTD, PSP, and CBS.
Synucleinopathies are neurodegenerative disorders caused by abnormal aggregation of alpha-synuclein proteins with formations of insoluble fibrils.
Alpha-synuclein aggregates are found in major families of synucleinopathies, which include Parkinson Disease (PD), Dementia with Lewy Bodies (DLB), and Multiple System Atrophy (MSA).
News
November 20, 2019
Initiation of a Phase 2 Multicenter Study of 18F-APN-1607, a Novel Diagnostic PET Imaging Tracer for the Characterization of Tau Burden in Alzheimer’s Disease
APRINOIA Therapeutics, Inc. announced today that it has initiated a Phase 2 multicenter, multinational study of 18F-APN-1607 in the US for its lead tau positron emission tomography (PET) tracer in Alzheimer's Disease (AD). The study (NCT number: NCT04141150) will compare tau deposition patterns in patients with mild cognitive impairment due to AD and dementia due to AD with patterns in healthy older adults.
August 29, 2019
APRINOIA Therapeutics has Initiated a Collaboration with Keio University in Tokyo, Japan
APRINOIA Therapeutics has initiated a collaboration with Keio University in Tokyo, Japan to profile patients with dementia using APRINOIA’s tau PET imaging tracer, 18F-APN-1607 (PM-PBB3). The collaboration is a part of the EKID (Eisai-Keio Innovation Laboratory for Dementia) study conducted by Keio University and Eisai Co. Ltd., which is supported by a research grant (No. JP17pc0101006) from AMED (Japan Agency for Medical Research and Development). APRINOIA is grateful for the opportunity to contribute to the study which might be useful for deeper understanding of dementia, especially Alzheimer’s Disease.
June 30, 2019
APRINOIA Therapeutics Joined JLABS @ Shanghai
APRINOIA Therapeutics, a clinical-stage biotechnology company with a pipeline of therapeutics and imaging diagnostics for neurodegenerative diseases, announces today that it has been selected to join Johnson & Johnson Innovation’s JLABS and is now a resident company of JLABS @ Shanghai.
For more information, please click on “More” for the original press release from Johnson & Johnson Innovation.
May 22, 2019
APRINOIA Therapeutics Awarded Grant from The Michael J. Fox Foundation for Parkinson’s Research
APRINOIA Therapeutics announces today that it has been awarded a research grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF) for the development of alpha-synuclein PET imaging tracers.
December 27, 2018
2019 Human Amyloid Imaging Conference
APRINOIA will be presenting the latest clinical trial results for its lead Tau PET Imaging Tracer APN-1607 (PM-PBB3) at the Human Amyloid Imaging (HAI) Conference in Miami, USA in January 2019. We will deliver a total of 10 presentations with our partners.
December 24, 2018
APRINOIA Licenses Tau PET Imaging Tracer APN-1607 to Celgene
APRINOIA Therapeutics announced today that it has entered into a non-exclusive licensing agreement with Celgene Corporation. The agreement authorizes Celgene to use APN-1607, a novel investigational [18F]-labeled positron emission tomography (PET) imaging tracer, to support patient selection and efficacy evaluation in its global clinical trials.
October 11, 2018
Emerging Company Profile - APRINOIA TACKLES TAU
Aprinoia Therapeutics Inc. is developing a pipeline targeting tauopathies that includes diagnostic imaging tracers, mAbs specific to pathologic tau and small molecules that bind to tau rather than dissociate tau aggregates.
“We are going to develop imaging biomarkers for all the therapeutic targets first to see those targets, and then find therapies,” CEO Ming-Kuei Jang told BioCentury.
August 31, 2018
Asia-China: 2018 Clinical Trials on Alzheimer's Disease Conference
APRINOIA will be sponsoring the first Clinical Trials on Alzheimer's Disease Conference (CTAD) in Asia. The conference will take place in Shanghai on September 1st and 2nd. APRINOIA will be presenting the latest clinical data of our lead tau PET Imaging tracer, APN-1607 (PM-PBB3), and the current progress of our therapeutics programs at the conference.
December 14, 2017
APRINOIA Closes US$11.1 Million Series B Financing
APRINOIA has completed its US$11.1 million Series B round. The Series B round was led by KTB Network (Korea) and DCI Partners (Japan), along with participations from ShangPharma Investment Group (China) and TaiAn Technologies (Taiwan). The proceeds of the funding will be used to finance preclinical and clinical development for APRINOIA’s tau centric programs.
December 11, 2016
2017 International Conference on Alzheimer's Disease and Parkinson's Disease
APRINOIA will be presenting the first-in-the-human clinical trial result for its lead Tau PET Imaging Tracer APN-1607 (PM-PBB3) at the 13th International Conference on Alzheimer's Disease and Parkinson's Disease (AD&PD) in Vienna in March 2017.
November 19, 2016
US FDA IND
APRINOIA has received written approval from the US FDA to conduct the first-in-the-human clinical trial in the US.
Careers
This information will be updated shortly.
Contact Us
台灣
Email ：
地址 ： 11503 臺北市南港區園區街3號17樓
辦公室電話： +886-2-2655-8868
Taiwan
Address ： 17F, No.3, Park St., Nangang District, Taipei City 11503
Phone ： +886-2-2655-8868
-------------------------------------------------------------------------------------------------------
中国大陆
邮箱 ：
地址 ： 苏州市工业园区星湖街218号 生物医药产业园B2号楼5楼503室 215123
办公室电话： +86-512-8777 8382
China
Address ： R503,5F,Building B2,218 Xing Hu Rd,Suzhou Industrial Park,Suzhou 215213
Phone ： +86-512-8777 8382
-------------------------------------------------------------------------------------------------------
日本
Email ：
所在地 ： 〒104ｰ0033 東京都中央区新川1-2-8 第5山京ビル5F
Tel ： +81-3-6280-4277
Japan
Address ： Shinkawa 1-2-8, Chuo-ku, Tokyo 104-0033, Japan
Phone ： +81-3-6280-4277